Preclinical Imaging Market

Global preclinical imaging market: The preclinical imaging process is used for monitoring the treatment responses helpful for obtaining the early indications of any disease. Preclinical imaging is used during drug discovery process on live animals. Technological improvements and advances in the in-vivo clinical study provides newer opportunities to understand it clearly on a molecular level. Major preclinical imaging is targeted for diseases such as autoimmune diseases, cancers, neurological and cardiovascular diseases, etc.

An increase of drug trials due to rise in the incidence and prevalence of chronic diseases such as rheumatoid arthritis, cancer, cardiovascular & neurological disorders, rise in the number of Contract Research Organizations (CRO), innovations in the devices used for small imaging technological advancements are some of factors boosting the market of preclinical imaging. However, the huge cost of equipment, lack of skilled personnel to handle the equipment and lack of proper infrastructure hampers the growth of the market. Furthermore, restrictions on animal drug testing by animal rights organizations are the major factors hampering the growth of the market.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-preclinical-imaging-market/#ulp-4H8Z4LpNMLEuOnnx

The Global preclinical imaging market is divided on the basis of -type of product, applications, and end-users.

1. Product type
• Imaging Modalities
• Single Photon emission computed tomography (SPECT)
• Micro Computed Tomography (Micro-CT)
• Magnetic Particle Imaging
• Magnetic Resonance Imaging (MRI)
• Optical Imaging
• X-Ray Imaging
• Positron Emission Tomography (PET)
• Ultrasound
• Others
• Reagents and Kits

2. Applications
• Research and Development
• Drug Discovery

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-preclinical-imaging-market/#ulp-c654SbFYO64MsOhu

3. End-users
Biotech Companies, Pharmaceutical companies and research institutes.

And lastly, geographically, global pre-clinical imaging market is categorized into Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. North America continues to hold the largest share due to increase in adoption of new technologies for better clinical outputs, technological advancements, and growing prevalence rates chronic diseases such as cardiovascular disease, cancer. According to the National Cancer Institute, in 2017, about 1,685,210 new cancer cases have been reported and diagnosed. Europe is expected to be another major market for preclinical imaging owing to factors such as an increase in healthcare awareness among people and R &D activity for treating and preventing diseases. Asia-Pacific preclinical imaging market expected to show lucrative growth opportunity owing to cost-effective clinical and preclinical imaging services, coupled with favorable government policies. Some of the key players in the global Preclinical Imaging market include FUJIFILM Holdings Corporation (Japan), MR Solutions (U.K.), PerkinElmer Inc. (U.S.), Siemens Ltd (U.S.), Miltenyi Biotec (Germany), Aspect Imaging (Canada), MILabs B.V. (Netherlands), Bruker Corporation (U.S.), Mediso Ltd. (Hungary), TriFoil Imaging (U.S.), and Carestream Health (U.S.) to name a few. In 2016, Bruker Corporation signed an agreement to obtain the preclinical imaging business of Oncovision to increase their product portfolio. In 2017, MR solutions introduced 9.4 Tesla cryogen preclinical MRI imaging solution for the cardiovascular sector.

Need more information about this report @